KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $301.3 million.

  • Nektar Therapeutics' Liabilities and Shareholders Equity fell 214.93% to $301.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 2604.04%. This contributed to the annual value of $303.8 million for FY2024, which is 2366.21% down from last year.
  • Per Nektar Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $301.3 million for Q3 2025, which was down 214.93% from $207.5 million recorded in Q2 2025.
  • Nektar Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $1.5 billion during Q1 2021, with a 5-year trough of $207.5 million in Q2 2025.
  • For the 5-year period, Nektar Therapeutics' Liabilities and Shareholders Equity averaged around $663.8 million, with its median value being $494.3 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first plummeted by 4514.85% in 2023, then tumbled by 214.93% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $1.1 billion in 2021, then tumbled by 36.39% to $710.6 million in 2022, then tumbled by 43.99% to $398.0 million in 2023, then fell by 23.66% to $303.8 million in 2024, then fell by 0.82% to $301.3 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $301.3 million for Q3 2025, versus $207.5 million for Q2 2025 and $256.2 million for Q1 2025.